# MARIPOSA-2 (NCT04988295)

> A Study of Amivantamab and Lazertinib in Combination With Platinum-Based Chemotherapy Compared With Platinum-Based Chemotherapy in Patients With Epidermal Growth Factor Receptor (EGFR)-Mutated Locally Advanced or Metastatic Non- Small Cell Lung Cancer After Osimertinib Failure

No report yet. It can be ordered.

## Registry

- Registry record: https://clinicaltrials.gov/study/NCT04988295
- Phase: PHASE3
- Status: ACTIVE_NOT_RECRUITING
- Sponsor: Janssen Research & Development, LLC
- Conditions: Carcinoma, Non-Small-Cell Lung
- Interventions: Lazertinib; Amivantamab; Pemetrexed; Carboplatin
- Enrollment: 776
- Primary outcome: Main Study: Progression-free Survival (PFS) According to Response Evaluation Criteria in Solid Tumors (RECIST) Version 1.1 as Assessed by Blinded Independent Central Review (BICR)
- Primary outcome: Main Study + Extension Cohort: Number of Participants With Treatment-emergent Adverse Events (TEAEs) and Treatment-emergent Serious Adverse Events (TESAEs)
- Primary outcome: Main Study + Extension Cohort: Progression-free Survival (PFS) as Assessed by Blinded Independent Central Review

## Commentary we found

- X threads: 164
- Podcasts: 110
- YouTube: 105
- X videos: 2

## Order

Deep, $1,950, price fixed at order: https://www.erudio.com/contact?report=mariposa-2-nct04988295

## Free build

POST https://www.erudio.com/api/trial-requests with {"nct_id": "NCT04988295", "email": "<work email>"}; the inbox owner confirms by the emailed link.